Ranbaxy to get royalty for Cipro XR sales in US

Tuesday, 17 December 2002, 20:30 IST
Printer Print Email Email
NEW DELHI: India's pharma major Ranbaxy Laboratories Monday said it would be receiving royalty from Bayer for marketing its urinary tract infection drug Cipro XR (Ciprofloxacin extended release tablets), which has been cleared by the U.S. Food and Drug Administration. Cipro XR, to be marketed in a dosage strength of 500 mg, is administered once a day for three days to treat uncomplicated urinary tract infections (UTIs). Cipro XR releases the active ingredient from two layers. The first releases ciprofloxacin into the blood within hours. This is followed by a second extended release of the active ingredient to allow sustained levels over 24 hours. Bayer had submitted the product for FDA approval for marketing in October 2002. It will begin shipping the products to U.S. pharmacies from January 2.
Source: IANS
siliconindia